|New pharmaceutical treatments are emerging as the standard of care for HIV treatment. Protease inhibitors used in combination with other antiretroviral medication are managing HIV viral load levels thereby enhancing the health and ability to remain employed for persons with HIV. Recent cost estimates indicate that current funding is not sufficient to support this program through Fiscal Year 1997. This funding assumes rebates of up to 15 percent for some of the new drugs. The following increases are estimated from May 1996 to June 1997: (1) enrollment from 813 to 1,150; (2) per capital costs from $400 per month to $600 per month; and (3) utilization from 32.5 percent to 50 percent.